DrugPatentWatch Database Preview

Details for Patent: 8,034,809

« Back to Dashboard

Which drugs does patent 8,034,809 protect, and when does it expire?

Patent 8,034,809 protects STIOLTO RESPIMAT and STRIVERDI RESPIMAT and is included in two NDAs.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 8,034,809

Title:	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Abstract:	Enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Inventor(s):	Lustenberger; Philipp (Basel, CH), Konetzki; Ingo (Warthausen, DE), Sieger; Peter (Mittelbiberach, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:	12/335,076
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,034,809

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes						TREATMENT OF COPD
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes						TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

Foreign Priority and PCT Information for Patent: 8,034,809

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2004 024 454	May 14, 2004

Non-Orange Book US Patents Family Members for Patent 8,034,809

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,220,742	Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
7,491,719	Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments

International Family Members for US Patent 8,034,809

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Russian Federation	2378262
Russian Federation	2006144123
Portugal	1789405
New Zealand	551416